$11.75

-0.76 (-6.08%)

11/21/2008 10:59 AM

Affymax, Inc. (AFFY)

CAPS Rating:

The Company is a biopharmaceutical company developing novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating AFFY

Add Stock to Watchlist

What the Community Thinks

Total Members

26 Outperforms

12 Underperforms

All-Stars

4 Outperforms

8 Underperforms

Wall Street

4 Outperforms

0 Underperforms

Members bullish on AFFY are also bullish on:

Members bearish on AFFY are also bearish on:

Ticker Tags

IPO in 2006 (158), Biotechnology (230), Micro Cap (4968)
Suggest a tag

Affymax, Inc. At A Glance

Current Price:	$11.75
Last Trade Time:	11/21/2008 10:59 AM
Open:	$12.37
Previous Close:	$12.51
Daily Range:	$11.75 - $12.37
52-Week Range:	$10.66 - $28.54
Volume:	17,485
Market Cap:	$191.43M
P/E Ratio:	1.83
Compare Our Special Broker Offers!

Stock Trends

AFFY VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for AFFY

Affymax ends part of Hematide development program
8/28/2008 4:23:00 PM - AP
Affymax wavers on forecast of Hematide approval
7/2/2008 5:39:00 PM - AP

More Headlines...

Top Bull Pitch

Recs

2 Affymax, Inc. (AFFY)

Avatar GBIGD (< 20) Submitted: 10/30/08 9:48 AM

MY MODEL TELLS ME TO MAKE THIS PICK

Replies: 1 | Reply | Permalink

Top Bear Pitch

Recs

1 Affymax, Inc. (AFFY)

Avatar NetscribeBiotech (85.19) Submitted: 3/27/07 9:14 AM

Affymax is a biopharmaceutical company creating peptide-based drugs to improve the treatment of serious and often life-threatening conditions. The company was spun out from GlaxoSmithKline in 2001. The company does not have any approved product in its portfolio. Its lead product candidate Hematide i...More

Replies: 1 | Reply | Permalink

Affymax is a biopharmaceutical company creating peptide-based drugs to improve the treatment of serious and often life-threatening conditions. The company was spun out from GlaxoSmithKline in 2001. The company does not have any approved product in its portfolio. Its lead product candidate Hematide is a synthetic peptide-based erythropoiesis-stimulating agent (ESA) in clinical development for anemia due to chronic kidney disease (CKD) and cancer. Besides this it has number of products in pre clinical phase for neutropenia, tissue protection and cancer.

The company is yet to break-even. However the company is in nascent stage and thus one can form a view on this company on the basis of its financial performance. The most relevant factor for such stocks would be the commercial potential of its pipe-line.

Affymax’s lead product candidate Hematide targets multi-billion-dollar worldwide EPO (erythropoietin) market for treating anemia. As a matter of fact The EPO market for anemia valued at $10.0 billion plus is the largest and most lucrative market in biotech at roughly plus worldwide and still growing. The drug has shown clear efficacy in Phase II trials and has the competitive advantage of less frequent dosing. The company has also roped in Takeda to market its product.

This budding company also has some issues to grapple with the chief among them would be arbitration with Johnson and Johnson to determine ownership of several key Hematide patents. In the event of an unfavorable outcome the company might have to share or lose the rights over patents.

The company’s valuation seems rich. It is true that its pipeline targets lucrative market opportunities but they will take some time to fructify. Hemadite for anemia is expected to enter Phase III in second half of 2007. The macro economic environment is such that people prefer stable cash flows and proven stories. Thus these types of stories which require people to bet aggressively on the future might not find favor in today’s market. Hence the company might under perform.

CAPS Members

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 4 of 4

Show Pitch Replies

Recs 0 (AFFY) equalfuture (93.90) Submitted: 4/10/08 4:50 AM : Start Price: $13.82 AFFY Score: 29.72 MAJOR BUY: 9 per share, i am buying when this company hits nine dollars, good price at 9 per share, can not go wrong, i am reaching for a nine dollar per share price for June. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (AFFY) TaurusRun (< 20) Submitted: 9/12/07 4:44 PM : Start Price: $27.50 AFFY Score: -7.67 A new twist on drug discovery Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (AFFY) ArlenesX (< 20) Submitted: 4/27/07 1:23 PM : Start Price: $34.04 AFFY Score: -15.60 IPO'd in 12/06. A great to superior market for the product, going into FDA stage 3. Once it is ok'd for sale it will reduce the dosage for anemia/cancer patients with kidney/dialysis related conditions by cutting treatment at least in half. The potential is enormous with the market growing everyday. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 1 (AFFY) NetscribeBiotech (85.19) Submitted: 3/27/07 9:14 AM : Start Price: $34.00 AFFY Score: 17.75 Affymax is a biopharmaceutical company creating peptide-based drugs to improve the treatment of serious and often life-threatening conditions. The company was spun out from GlaxoSmithKline in 2001. The company does not have any approved product in its portfolio. Its lead product candidate Hematide is a synthetic peptide-based erythropoiesis-stimulating agent (ESA) in clinical development for anemia due to chronic kidney disease (CKD) and cancer. Besides this it has number of products in pre clinical phase for neutropenia, tissue protection and cancer. The company is yet to break-even. However the company is in nascent stage and thus one can form a view on this company on the basis of its financial performance. The most relevant factor for such stocks would be the commercial potential of its pipe-line. Affymax’s lead product candidate Hematide targets multi-billion-dollar worldwide EPO (erythropoietin) market for treating anemia. As a matter of fact The EPO market for anemia valued at $10.0 billion plus is the largest and most lucrative market in biotech at roughly plus worldwide and still growing. The drug has shown clear efficacy in Phase II trials and has the competitive advantage of less frequent dosing. The company has also roped in Takeda to market its product. This budding company also has some issues to grapple with the chief among them would be arbitration with Johnson and Johnson to determine ownership of several key Hematide patents. In the event of an unfavorable outcome the company might have to share or lose the rights over patents. The company’s valuation seems rich. It is true that its pipeline targets lucrative market opportunities but they will take some time to fructify. Hemadite for anemia is expected to enter Phase III in second half of 2007. The macro economic environment is such that people prefer stable cash flows and proven stories. Thus these types of stories which require people to bet aggressively on the future might not find favor in today’s market. Hence the company might under perform. Report this Post Replies: 1 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 4 of 4

Wall Street

Results 1 - 4 of 4

picks per page. CHANGE

Top Pick	Member Name	Member Rating	Start Date	Call	Time Frame	Start Price	Stock Gain	S&P Gain	Score	Pitch
	TrackStanfordRes	< 20	09/24/08		NS	$18.90	-37.83%	-37.06%	-0.77
	TrackRWBaird	32.68	07/02/08		NS	$16.15	-27.24%	-41.93%	+14.69
	TrackRBCCapMkts	< 20	07/17/07		NS	$27.56	-57.37%	-51.78%	-5.58
	TrackCowenandCo	49.20	03/14/07		NS	$31.50	-62.70%	-45.91%	-16.78

Results 1 - 4 of 4

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.